<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986245</url>
  </required_header>
  <id_info>
    <org_study_id>0908-037-290</org_study_id>
    <nct_id>NCT00986245</nct_id>
  </id_info>
  <brief_title>Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily</brief_title>
  <official_title>An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. In order to compare the benefit, side effects, and patient preference of Ropinirole
           prolonged release when used in once-daily or twice-daily dosing

        2. In order to estimate the conversion rate of dopamine agonists into Ropinirole prolonged
           release
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study subjects : Parkinson disease who are on Ropinirole immediate release or
           Pramipexole immediate release and are considering to change into Ropinirole prolonged
           release

        2. Cross over study design:

             -  Group 1: once daily dose for 2 month then into twice daily in divided dose for 2
                months

             -  Group 2: twice daily in divided dose for 2 months then into once daily dose for 2
                months

        3. Dose adjustment may be done in the first 4 weeks.

        4. Compare the benefit,side effects, and patient preference between the once daily vs twice
           daily dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Preference</measure>
    <time_frame>After 16 weeks or at last visit for early completion</time_frame>
    <description>Patient preference between once-daily and twice-daily regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale, Part 3</measure>
    <time_frame>8 weeks for each arm or at last visit</time_frame>
    <description>Unified Parkinson's disease rating scale (UPDRS) motor scale after 8 weeks in each arm or at last visit for early completion.
UPDRS part 3 is motor scale for parkinson's disease. Range: 0~108 Higher values represent more severe motor symptoms of parkinsonism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoehn and Yahr Stage</measure>
    <time_frame>8 weeks for each arm or at last visit</time_frame>
    <description>Hoehn and Yahr(HY) stage for parkinsonism after 8 weeks in each arm or at last visit for early completion Range: 0~5 Higher values represent more severe parkinsonism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Quality of Sleep</measure>
    <time_frame>8 weeks for each arm or at last visit</time_frame>
    <description>Sleep questionnaire 1 for &quot;Overall quality of sleep&quot; Visual analogue scale: 0~10 Higher values represent worse overall sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Off-symptoms</measure>
    <time_frame>8 weeks for each arm or at last visit</time_frame>
    <description>Sleep questionnaire 2 for &quot;Nocturnal off-symptoms&quot; Visual analogue scale: 0~10 Higher values represent worse nocturnal off-symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Morning Off Symptoms</measure>
    <time_frame>8 weeks for each arm or at last visit</time_frame>
    <description>Sleep questionnaire 3 for &quot;early morning off symptoms&quot; Visual analogue scale: 0~10 Higher values represent worse early morning off symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleep Scale</measure>
    <time_frame>8 weeks in each arm or at last visit for early completion</time_frame>
    <description>Epworth sleep scale after 8 weeks in each arm or at last visit for early completion.
Range: 0~24 Higher values represent worse daytime-sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>8 weeks for each arm or at last visit</time_frame>
    <description>Compliances after 8 weeks in each arm or at last visit for early completion. Compliance was calcuated by the percentage of used medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
    <description>Patients who have adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Have Global Impression for Improvement</measure>
    <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
    <description>Patients who have global impression for improvement for each dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Have Global Impression for Improvement to Duration of Motor Fluctuation</measure>
    <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
    <description>Patients who have global impression for improvement to duration of motor fluctuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Have Global Impression for Improvement to Severity of Motor Fluctuation</measure>
    <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
    <description>Patients who have global impression for improvement to severity of motor fluctuation compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Have Global Impression for Improvement to Duration of Dyskinesia</measure>
    <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
    <description>Patients who have global impression for improvement to duration of dyskinesia compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Have Global Impression for Improvement to Severity of Dyskinesia</measure>
    <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
    <description>Patients who have Global Impression for Improvement to Severity of Dyskinesia compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Ropinirole PR QD first, then BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropinirole PR BID first, and then QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole Prolonged release</intervention_name>
    <description>Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily</description>
    <arm_group_label>Ropinirole PR QD first, then BID</arm_group_label>
    <arm_group_label>Ropinirole PR BID first, and then QD</arm_group_label>
    <other_name>Requip PDÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 30-80

          2. Parkinson disease

          3. On dopamine agonists (Ropinirole IR or Pramipexole IR) and are considering to change
             into Ropinirole PR

          4. On stable antiparkinsonian medication for at least 4 weeks

          5. Who signed consent to the study

        Exclusion Criteria:

          1. Who are on less than 2 mg of Ropinirole IR or 0.375 mg of Pramipexole IR

          2. Who have dementia, psychosis, major depression and other serious neurological or
             medical problems

          3. Who are allergic to the similar medications

          4. Who has history of heavy metal poisoning

          5. Who were on othe clinical trials of other medications within the last 4 weeks

          6. Whoa re pregnant or lactating

          7. Who are considered not eligible by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beom S Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boramae City Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lyons KE, Pahwa R. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease. Mov Disord. 2009 Oct 30;24(14):2121-7. doi: 10.1002/mds.22750.</citation>
    <PMID>19768728</PMID>
  </reference>
  <reference>
    <citation>Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L; Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008 Oct;24(10):2883-95. doi: 10.1185/03007990802387130 . Epub 2008 Sep 2.</citation>
    <PMID>18768106</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <results_first_submitted>July 7, 2012</results_first_submitted>
  <results_first_submitted_qc>September 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2013</results_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>BS Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>Ropinirole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled in September 2009 and the last subject completed the study in December 2010.</recruitment_details>
      <pre_assignment_details>A total of 82 patients with PD were enrolled in this study at two centers in Seoul, Korea.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ropinirole PR-Once Daily First, Then Twice Daily</title>
          <description>Ropinirole prolonged release(PR) once daily in first intervention period and twice daily in second intervention period (without washout period)</description>
        </group>
        <group group_id="P2">
          <title>Ropinirole PR-Twice Daily First, Then Once Daily</title>
          <description>Ropinirole prolonged release(PR) twice daily in first intervention period and once daily in second intervention period (without washout period)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Poor compliance</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Out of indication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Poor compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive once daily first and twice daily first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Preference</title>
        <description>Patient preference between once-daily and twice-daily regimen</description>
        <time_frame>After 16 weeks or at last visit for early completion</time_frame>
        <population>Primary outcome measure was the preference of the subjects between once-daily versus twice-daily of RPR at the completion or at early completion after crossover.
61 of participants completing period with study intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily</title>
            <description>Once-daily preferred group</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily</title>
            <description>Twice-daily preferred group</description>
          </group>
          <group group_id="O3">
            <title>No Preference</title>
            <description>No preference group</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Preference</title>
          <description>Patient preference between once-daily and twice-daily regimen</description>
          <population>Primary outcome measure was the preference of the subjects between once-daily versus twice-daily of RPR at the completion or at early completion after crossover.
61 of participants completing period with study intervention.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unified Parkinson's Disease Rating Scale, Part 3</title>
        <description>Unified Parkinson's disease rating scale (UPDRS) motor scale after 8 weeks in each arm or at last visit for early completion.
UPDRS part 3 is motor scale for parkinson's disease. Range: 0~108 Higher values represent more severe motor symptoms of parkinsonism.</description>
        <time_frame>8 weeks for each arm or at last visit</time_frame>
        <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. Once-daily or Twice-daily arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole Prolonged release administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole Prolonged release administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale, Part 3</title>
          <description>Unified Parkinson's disease rating scale (UPDRS) motor scale after 8 weeks in each arm or at last visit for early completion.
UPDRS part 3 is motor scale for parkinson's disease. Range: 0~108 Higher values represent more severe motor symptoms of parkinsonism.</description>
          <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. Once-daily or Twice-daily arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="8.2"/>
                    <measurement group_id="O2" value="17.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The UPDRS-part3 was compared between the Once-daily of Ropinirole PR arm and the Twice-daily of Ropinirole PR using the Wilcoxon signed rank test.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>80% power</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Sign test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hoehn and Yahr Stage</title>
        <description>Hoehn and Yahr(HY) stage for parkinsonism after 8 weeks in each arm or at last visit for early completion Range: 0~5 Higher values represent more severe parkinsonism</description>
        <time_frame>8 weeks for each arm or at last visit</time_frame>
        <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. Once-daily or twice-daily arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Hoehn and Yahr Stage</title>
          <description>Hoehn and Yahr(HY) stage for parkinsonism after 8 weeks in each arm or at last visit for early completion Range: 0~5 Higher values represent more severe parkinsonism</description>
          <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. Once-daily or twice-daily arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.5"/>
                    <measurement group_id="O2" value="2.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Hoehn and Yahr stage was compared between the Once-daily of Ropinirole PR arm and the Twice-daily of Ropinirole PR using the Wilcoxon signed rank test.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>80% power</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Sign test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.0</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Quality of Sleep</title>
        <description>Sleep questionnaire 1 for &quot;Overall quality of sleep&quot; Visual analogue scale: 0~10 Higher values represent worse overall sleep quality.</description>
        <time_frame>8 weeks for each arm or at last visit</time_frame>
        <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Quality of Sleep</title>
          <description>Sleep questionnaire 1 for &quot;Overall quality of sleep&quot; Visual analogue scale: 0~10 Higher values represent worse overall sleep quality.</description>
          <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.6"/>
                    <measurement group_id="O2" value="3.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The &quot;Overall quality of sleep&quot; was compared between the Once-daily of Ropinirole PR arm and the Twice-daily of Ropinirole PR using the Wilcoxon signed rank test.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>80% power</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Sign test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.3</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nocturnal Off-symptoms</title>
        <description>Sleep questionnaire 2 for &quot;Nocturnal off-symptoms&quot; Visual analogue scale: 0~10 Higher values represent worse nocturnal off-symptoms.</description>
        <time_frame>8 weeks for each arm or at last visit</time_frame>
        <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal Off-symptoms</title>
          <description>Sleep questionnaire 2 for &quot;Nocturnal off-symptoms&quot; Visual analogue scale: 0~10 Higher values represent worse nocturnal off-symptoms.</description>
          <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.2"/>
                    <measurement group_id="O2" value="3.1" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The &quot;Nocturnal off-symptoms&quot; was compared between the Once-daily of Ropinirole PR arm and the Twice-daily of Ropinirole PR using the Wilcoxon signed rank test.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>80% power</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Sign test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Morning Off Symptoms</title>
        <description>Sleep questionnaire 3 for &quot;early morning off symptoms&quot; Visual analogue scale: 0~10 Higher values represent worse early morning off symptoms.</description>
        <time_frame>8 weeks for each arm or at last visit</time_frame>
        <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Morning Off Symptoms</title>
          <description>Sleep questionnaire 3 for &quot;early morning off symptoms&quot; Visual analogue scale: 0~10 Higher values represent worse early morning off symptoms.</description>
          <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="3.3"/>
                    <measurement group_id="O2" value="2.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The &quot;Early morning off symptoms&quot; was compared between the Once-daily of Ropinirole PR arm and the Twice-daily of Ropinirole PR using the Wilcoxon signed rank test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>80% power</p_value_desc>
            <method>Sign test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleep Scale</title>
        <description>Epworth sleep scale after 8 weeks in each arm or at last visit for early completion.
Range: 0~24 Higher values represent worse daytime-sleepiness.</description>
        <time_frame>8 weeks in each arm or at last visit for early completion</time_frame>
        <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleep Scale</title>
          <description>Epworth sleep scale after 8 weeks in each arm or at last visit for early completion.
Range: 0~24 Higher values represent worse daytime-sleepiness.</description>
          <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="5.2"/>
                    <measurement group_id="O2" value="6.4" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The &quot;Epworth sleep scale&quot; was compared between the Once-daily of Ropinirole PR arm and the Twice-daily of Ropinirole PR using the Wilcoxon signed rank test.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>80% power</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Sign test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance</title>
        <description>Compliances after 8 weeks in each arm or at last visit for early completion. Compliance was calcuated by the percentage of used medication.</description>
        <time_frame>8 weeks for each arm or at last visit</time_frame>
        <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance</title>
          <description>Compliances after 8 weeks in each arm or at last visit for early completion. Compliance was calcuated by the percentage of used medication.</description>
          <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
          <units>percentage of used medication</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" spread="3.9"/>
                    <measurement group_id="O2" value="97.6" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Sign test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.8</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Patients who have adverse events</description>
        <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
        <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Patients who have adverse events</description>
          <population>Total number of patients are 61 (Group 1 + Group 2), because of Crossover design. QD or BID arm means clinical variables measured in once-daily or twice-daily regimen, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Have Global Impression for Improvement</title>
        <description>Patients who have global impression for improvement for each dosing.</description>
        <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
        <population>The number of patient who completed the study and answered the questionnaire for global impression.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Have Global Impression for Improvement</title>
          <description>Patients who have global impression for improvement for each dosing.</description>
          <population>The number of patient who completed the study and answered the questionnaire for global impression.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Have Global Impression for Improvement to Duration of Motor Fluctuation</title>
        <description>Patients who have global impression for improvement to duration of motor fluctuation</description>
        <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
        <population>The number of patient who completed the study and answered the questionnaire for global impression to motor fluctuation duration.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Have Global Impression for Improvement to Duration of Motor Fluctuation</title>
          <description>Patients who have global impression for improvement to duration of motor fluctuation</description>
          <population>The number of patient who completed the study and answered the questionnaire for global impression to motor fluctuation duration.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Have Global Impression for Improvement to Severity of Motor Fluctuation</title>
        <description>Patients who have global impression for improvement to severity of motor fluctuation compared</description>
        <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
        <population>The number of patient who completed the study and answered the questionnaire for global impression to motor fluctuation severity.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Have Global Impression for Improvement to Severity of Motor Fluctuation</title>
          <description>Patients who have global impression for improvement to severity of motor fluctuation compared</description>
          <population>The number of patient who completed the study and answered the questionnaire for global impression to motor fluctuation severity.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Have Global Impression for Improvement to Duration of Dyskinesia</title>
        <description>Patients who have global impression for improvement to duration of dyskinesia compared</description>
        <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
        <population>The number of patient who completed the study and answered the questionnaire for global impression to dyskinesia duration.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Have Global Impression for Improvement to Duration of Dyskinesia</title>
          <description>Patients who have global impression for improvement to duration of dyskinesia compared</description>
          <population>The number of patient who completed the study and answered the questionnaire for global impression to dyskinesia duration.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Have Global Impression for Improvement to Severity of Dyskinesia</title>
        <description>Patients who have Global Impression for Improvement to Severity of Dyskinesia compared</description>
        <time_frame>After 8 weeks in each arm or at last visit for early completion</time_frame>
        <population>The number of patient who completed the study and answered the questionnaire for global impression to dyskinesia severity.</population>
        <group_list>
          <group group_id="O1">
            <title>Once-daily of Ropinirole PR</title>
            <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Twice-daily of Ropinirole PR</title>
            <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Have Global Impression for Improvement to Severity of Dyskinesia</title>
          <description>Patients who have Global Impression for Improvement to Severity of Dyskinesia compared</description>
          <population>The number of patient who completed the study and answered the questionnaire for global impression to dyskinesia severity.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks for each arm or at last visit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Once-daily of Ropinirole PR</title>
          <description>Once-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
        </group>
        <group group_id="E2">
          <title>Twice-daily of Ropinirole PR</title>
          <description>Twice-daily regimen of Ropinirole PR administered in either first intervention peirod or second intervention period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="61"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Aggravation of vivid dream or REM sleep behavior disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was designed to open-label study. We cannot exclude the psychological effect of each regimen.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>BS Jeon</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>82-2-2072-2876</phone>
      <email>brain@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

